- Motley Fool•2 hours ago
Eli Lilly's Alzheimer’s program is a bust. Does the market’s overreaction make this Big Pharma stock more attractive than Johnson & Johnson's right now?
- American City Business Journals•8 hours ago
Thursday is shaping up to be one of the most important days for Biogen in recent memory, as the Cambridge biotech prepares to announce data from a trial of a potentially groundbreaking — and extremely lucrative — Alzheimer’s drug. Biogen (BIIB) has a lot riding on the early-stage results for aducanumab, which are scheduled to be announced at the Clinical Trials for Alzheimer's Disease, an annual industry conference in San Diego. The recent failure of a similar Alzheimer’s treatment at Eli Lilly (LLY) cast doubt on the theory that amyloid causes memory loss, and sent Biogen’s share price tumbling .
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's (SGLT-2 inhibitor) label.
LLY : Summary for Eli Lilly and Company Common St - Yahoo Finance
Eli Lilly and Company (LLY)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Bid||67.36 x 900|
|Ask||67.37 x 700|
|Day's Range||66.56 - 67.38|
|52 Week Range||64.18 - 87.21|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.31|
|Dividend & Yield||2.04 (3.01%)|
|1y Target Est||N/A|